These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2589364)

  • 1. Intravenous ciprofloxacin therapy in severe infections.
    Gudiol F; Cabellos C; Pallares R; Linares J; Ariza J
    Am J Med; 1989 Nov; 87(5A):221S-224S. PubMed ID: 2589364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of serious infections with intravenous ciprofloxacin. French Multicenter Study Group.
    Modai J
    Am J Med; 1989 Nov; 87(5A):243S-247S. PubMed ID: 2686426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections.
    Fass RJ; Plouffe JF; Russell JA
    Am J Med; 1989 Nov; 87(5A):164S-168S. PubMed ID: 2589361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of intravenous ciprofloxacin in difficult-to-treat infections.
    Giamarellou H; Galanakis N
    Am J Med; 1987 Apr; 82(4A):346-51. PubMed ID: 3555059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of ciprofloxacin therapy for gram-negative bacillary osteomyelitis.
    Hessen MT; Ingerman MJ; Kaufman DH; Weiner P; Santoro J; Korzeniowski OM; Boscia J; Topiel M; Bush LM; Kaye D
    Am J Med; 1987 Apr; 82(4A):262-5. PubMed ID: 3555045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections.
    Peacock JE; Pegram PS; Weber SF; Leone PA
    Am J Med; 1989 Nov; 87(5A):185S-190S. PubMed ID: 2686421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous/oral ciprofloxacin therapy versus intravenous ceftazidime therapy for selected bacterial infections.
    Gaut PL; Carron WC; Ching WT; Meyer RD
    Am J Med; 1989 Nov; 87(5A):169S-175S. PubMed ID: 2686417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli.
    Gilbert DN; Tice AD; Marsh PK; Craven PC; Preheim LC
    Am J Med; 1987 Apr; 82(4A):254-8. PubMed ID: 3555044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous ciprofloxacin or ceftazidime in selected infections. A prospective, randomized, controlled study.
    Villavicencio J; Asensio de Fernandez ME; Ramirez CA
    Am J Med; 1989 Nov; 87(5A):191S-194S. PubMed ID: 2686422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral ciprofloxacin therapy for gram-negative bacillary osteomyelitis.
    Lesse AJ; Freer C; Salata RA; Francis JB; Scheld WM
    Am J Med; 1987 Apr; 82(4A):247-53. PubMed ID: 3555043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of serious infections with intravenous ciprofloxacin.
    Scully BE; Neu HC
    Am J Med; 1987 Apr; 82(4A):369-75. PubMed ID: 3555062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous/oral ciprofloxacin therapy of infections caused by multiresistant bacteria.
    Neu HC; Davidson S; Briones F
    Am J Med; 1989 Nov; 87(5A):209S-212S. PubMed ID: 2511758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim/sulfamethoxazole-resistant bacteria.
    Preheim LC; Cuevas TA; Roccaforte JS; Mellencamp MA; Bittner MJ
    Am J Med; 1987 Apr; 82(4A):295-300. PubMed ID: 3555051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous ciprofloxacin and ceftazidime in serious infections. A prospective, controlled clinical trial with third-party blinding.
    Sifuentes-Osornio J; Macías A; Amieva RI; Ramos A; Ruiz-Palacios GM
    Am J Med; 1989 Nov; 87(5A):202S-205S. PubMed ID: 2686425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the safety and efficacy of intravenous ciprofloxacin and intravenous ceftazidime in the treatment of selected infections.
    Gallis HA; Brennan RO; Goodwin SD; Swinney V; Rumbaugh MM; Drew RH
    Am J Med; 1989 Nov; 87(5A):176S-180S. PubMed ID: 2686418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of sepsis in patients with neoplastic diseases with intravenous ciprofloxacin.
    Brown AE; Smith G
    Am J Med; 1989 Nov; 87(5A):266S-268S. PubMed ID: 2589376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics.
    Nix DE; Cumbo TJ; Kuritzky P; DeVito JM; Schentag JJ
    Am J Med; 1987 Apr; 82(4A):146-53. PubMed ID: 3555029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of intravenous ciprofloxacin in the treatment of selected infections.
    Abadie-Kemmerly S; Pankey GA
    Am J Med; 1989 Nov; 87(5A):213S-220S. PubMed ID: 2589363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ciprofloxacin in patients with bacteremic infections. The Spanish Group for the Study of Ciprofloxacin.
    Bouza E; Díaz-López MD; Bernaldo de Quirós JC; Rodríguez-Créixems M
    Am J Med; 1989 Nov; 87(5A):228S-231S. PubMed ID: 2589366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections.
    Nix DE; Sands MF; Peloquin CA; Vari AJ; Cumbo TJ; Vance JW; Fracasso JE; Schentag JJ
    Am J Med; 1987 Apr; 82(4A):352-6. PubMed ID: 3555060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.